Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag087 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Xueyi Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Rifabutin, Tuberculosis, Meningeal, Rifampin, Antitubercular Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Tuberculous meningitis (TB meningitis), the most severe form of tuberculosis (TB), carries high mortality and neurological sequelae, and current rifampin-based regimen are limited by poor central nervous system penetration. Alternative rifamycins like rifapentine and rifabutin, with different pharmacokinetic profiles, are effective for treating drug-susceptible pulmonary TB, with rifapentine now forming the basis of a WHO-approved 4-month daily rifapentine-moxifloxacin regimen, and retrospective studies showing that rifabutin-based regimens are effective and well-tolerated, both drugs still need dedicated evaluation in TB meningitis.
Methods
Mice were intracranially inoculated with Mycobacterium tuberculosis and treated with rifamycin (rifampin, rifapentine or rifabutin)-based regimens at human equipotent doses. We assessed the bactericidal activities of the three regimens, rifamycin tissue concentrations, brain inflammation [brain magnetic resonance imaging (MRI), tissue immunofluorescence, cytokines] and neuronal injury.
Results
Both rifapentine- and rifabutin-containing regimens demonstrated bactericidal activity in the brain, similar to or better than the standard rifampin-containing regimen, as well as reduced neuroinflammation and brain injury.
Conclusion
Alternate rifamcyins, rifapentine and rifabutin, show therapeutic activity and neuroprotective effects, supporting their evaluation in clinical trials for treating TB meningitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Cincinnati Children's Center for Molecular Imaging and Precision Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
- Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Xueyi Chen, Yuderleys Masias-Leon, Medha Singh, Oscar J Nino-Meza, Charles A Peloquin, Dmitri Artemov, Sanjay K Jain
Förderung
- NIH HHS
- NIAID NIH HHS
Zitieren
APA
Chen, X., Ruiz-Gonzalez, C. E., Masias-Leon, Y., Singh, M., Nino-Meza, O. J., Peloquin, C. A., Artemov, D., & Jain, S. K. (2026). Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag087
Vancouver
Chen X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, Nino-Meza OJ, Peloquin CA, et al. Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag087
BibTeX
@article{Chen2026,
author = {Chen, Xueyi and Ruiz-Gonzalez, Carlos E and Masias-Leon, Yuderleys and Singh, Medha and Nino-Meza, Oscar J and Peloquin, Charles A and Artemov, Dmitri and Jain, Sanjay K},
title = {Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag087}
}
EUVIMED